ClinicalTrials.gg
CompletedNCT07810127Updated Sep 9, 2026

EXPLORATORY STUDY OF THE POTENTIAL OF THERAPEUTIC EXERCISE IN THE TREATMENT OF WILLIS-EKBOM DISEASE

An interventional study of Myofascial Self-Stretching Exercise Program and Buerger-Allen Exercise Program in Willis-Ekbom Disease and Restless Legs Syndrome (RLS), sponsored by Universidad Pontificia Comillas. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Universidad Pontificia Comillas · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Mar 2026, registered Sep 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 11 studies in Restless Legs Syndrome with a site in Spain — none open to participants now, none under way, none of them phase 3. Restless Legs Syndrome · Spain.

Enrollment
10th of 10
27 · median 350
Started
2026
the only one that year
No phase
Only one
of the 11
Registered
11th of 11
by date
Lead sponsor
1 of 11
Universidad Pontificia Comillas

Among the 11 studies in Restless Legs Syndrome with a site in Spain, this one is the 10th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2026, is the only one with no phase, and was the 11th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 11 studies in Restless Legs Syndrome with a site in Spain is open now. The open studies under Restless Legs Syndrome, anywhere →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Restless Legs Syndrome with a site in Spain as a file.
02

Study summary

The goal of this clinical trial is to learn whether a home-based therapeutic exercise program can improve symptoms of restless legs syndrome (RLS), also known as Willis-Ekbom disease, in adults with chronic RLS. It will also assess whether the program affects daytime sleepiness and quality of life, and whether participants can follow and tolerate the exercises.

The main questions it aims to answer are:

  • Does a myofascial self-stretching routine improve RLS symptoms?
  • Does the exercise program affect daytime sleepiness and quality of life?

Researchers will compare two low-risk home exercise routines: a myofascial self-stretching program based on Mézières and Global Active Stretching principles and Buerger-Allen exercises. Participants will be assigned to one of two exercise sequences and will complete their routine over 2 weeks.

Participants will:

  • complete a clinical assessment at the start and end of the study;
  • perform a 10- to 20-minute exercise session at home each night, preferably before bedtime;
  • record their RLS symptoms each day; and
  • keep their usual RLS medication stable during the study.
Read the detailed description

Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder characterized by an urge to move the legs, usually accompanied by unpleasant sensations that begin or worsen during rest and are more prominent in the evening or at night. Pharmacological treatments are available, but some people have an insufficient response, experience adverse effects, or develop worsening of symptoms over time. This exploratory study evaluates a non-pharmacological and non-invasive home-based exercise approach intended to provide preliminary evidence for future studies.

The investigational exercise program consists of self-administered myofascial stretching derived from the Mézières therapeutic approach and Global Active Stretching. The exercises combine sustained low-load muscle activity, low-intensity stretching, controlled breathing with emphasis on expiration, and focused attention to posture and movement. The comparator is a Buerger-Allen exercise routine based mainly on lower-limb positioning and ankle movements. No investigational drug or medical device is used.

The study uses a randomized, two-sequence design. Participants complete 2 weeks of home-based exercise. One group of participants performs the myofascial self-stretching routine and the other group completes the Buerger-Allen exercise routine. Allocation is intended to maintain comparable groups with respect to relevant participant characteristics. Participants are not told which routine is hypothesized to have a greater effect on RLS symptoms, and the evaluating research team is blinded to group assignment. Participants are also asked not to discuss their assigned exercise routines with other participants.

Participants are recruited from volunteers linked to the Spanish Restless Legs Syndrome Association (Asociación Española de Piernas Inquietas, AESPI). Clinical eligibility and the diagnosis of RLS are confirmed by a neurologist. Exercise instructions are provided before the intervention, with the possibility of in-person or remote participation for people living outside the Madrid region. Participants receive detailed instructional material, including videos and written guidance, and perform the exercises independently at home, preferably shortly before bedtime. Usual RLS medication is kept stable during the study unless a treating physician determines that a change is clinically necessary.

Clinical assessments are performed at the beginning and end of the study using validated measures of RLS symptom severity, daytime sleepiness, and health-related quality of life. Participants also record symptom intensity daily and may report comments about sleep, discomfort, symptoms, or difficulties with the exercises. Baseline information includes relevant clinical and lifestyle variables and recent laboratory measures related to iron metabolism. AESPI collects participant-reported information and provides pseudonymized data to the research team.

The analysis is exploratory. Quantitative variables will be summarized using means and standard deviations or medians and interquartile ranges, as appropriate, and categorical variables using frequencies and percentages. Changes over time will be evaluated using paired statistical tests, with non-parametric methods used when appropriate for the sample size and data distribution. Associations between variables will be explored using correlation analyses. Statistical significance will be assessed using a two-sided threshold of p \< 0.05.

The study is intended to explore the therapeutic potential, tolerability, and feasibility of a simple home-based exercise program. It is not designed to replace established RLS treatments or to provide definitive evidence of clinical efficacy.

03

Conditions studied

  • Willis-Ekbom Disease
  • Restless Legs Syndrome (RLS)

Keywords

  • Restless Legs Syndrome
  • Willis-Ekbom Disease
  • Myofascial Stretching
  • Mézières Method
  • Non-Pharmacological Intervention
  • Therapeutic Exercise
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.
  • Resident in Spain, preferably in or near the Community of Madrid.
  • Clinical diagnosis of restless legs syndrome (RLS) according to the 2014 International Restless Legs Syndrome Study Group (IRLSSG) diagnostic criteria, confirmed through clinical assessment by a neurologist.
  • Symptoms predominantly affecting the legs.
  • Under medical follow-up for at least 3 months before enrollment, regardless of current treatment or response to medication.
  • If receiving pharmacological treatment for RLS, treatment must have remained stable for at least 1 month before enrollment and must remain stable throughout the study.

Exclusion criteria

Exclusion Criteria:

  • Acute or chronic musculoskeletal conditions, such as symptomatic disc herniation, radiculopathy, severe tendinopathy, recent muscle injury, or advanced osteoarthritis, that limit or contraindicate prolonged stretching exercises.
  • Severe uncontrolled pain in the lumbar region, pelvis, or lower extremities that prevents completion of the stretching positions required by the protocol.
  • Initiation, concurrently with this study, of another non-pharmacological therapy for RLS, such as vibration or compression devices, yoga, or dietary supplements.
  • Epilepsy or any other concomitant neurological or neuromuscular disease affecting muscle tone, strength, or postural control that could interfere with the study.
  • Pharmacological treatment requiring frequent adjustments that would prevent treatment stability during the study.
  • Significant functional limitations, including balance problems, reduced mobility, inability to perform exercises on the floor, or inability to maintain prolonged positions, that prevent correct performance of the exercise protocol.
  • Insomnia unrelated to RLS.
  • Pregnancy or breastfeeding.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Myofascial Self-Stretching Exercise Program

    Participants perform a home-based myofascial self-stretching exercise program derived from the Mézières therapeutic approach and Global Active Stretching. The exercises combine sustained low-load muscle activity, low-intensity stretching, controlled breathing, and postural control. The routine is performed in the evening, preferably shortly before bedtime, for approximately 15-20 minutes per session.

    Behavioral: Myofascial Self-Stretching Exercise Program

  • Active comparator
    Buerger-Allen Exercise Program

    Participants perform a home-based Buerger-Allen exercise program involving lower-limb positioning and ankle movements. The routine is performed in the evening, preferably shortly before bedtime, for approximately 10-15 minutes per session. This exercise program is used as the comparator intervention and is not expected to have a specific therapeutic effect on restless legs syndrome symptoms.

    Behavioral: Buerger-Allen Exercise Program

Interventions

  • BehavioralMyofascial Self-Stretching Exercise Program

    Participants perform a home-based myofascial self-stretching exercise program derived from the Mézières therapeutic approach and Global Active Stretching. The program combines sustained low-load activation of agonist muscles, sustained low-intensity stretching of antagonist muscles, controlled breathing with emphasis on expiration, and postural and attentional control. The exercises are performed progressively according to each participant's capabilities. Each session lasts approximately 15 to 20 minutes and is performed in the evening, preferably shortly before bedtime.

  • BehavioralBuerger-Allen Exercise Program

    Participants perform a home-based Buerger-Allen exercise program consisting of a sequence of three exercises involving changes in lower-limb position and repeated ankle movements. The routine includes ankle flexion-extension movements with the legs elevated, circular ankle movements while seated with the legs hanging, and repeated ankle flexion-extension movements while lying down. Each exercise is performed for approximately 3 to 5 minutes, resulting in a total session duration of approximately 10 to 15 minutes. The sessions are performed in the evening, preferably shortly before bedtime.

06

What researchers measure

Primary outcomes

  1. Change in Restless Legs Syndrome Symptom Severity Assessed by the International Restless Legs Scale (IRLS)

    The International Restless Legs Scale (IRLS) is a 10-item questionnaire used to assess the severity of restless legs syndrome symptoms. Each item is scored from 0 to 4, resulting in a total score ranging from 0 to 40, with higher scores indicating greater symptom severity. The outcome is the change in total IRLS score from baseline to the end of the intervention.

    Time frame: Baseline and end of the 2-week intervention

Secondary outcomes

  1. Change in Daytime Sleepiness Assessed by the Epworth Sleepiness Scale (ESS)

    Daytime sleepiness is assessed using the Epworth Sleepiness Scale (ESS), an 8-item questionnaire in which each item is scored from 0 to 3. Total scores range from 0 to 24, with higher scores indicating greater daytime sleepiness. The outcome is the change in total ESS score from baseline to the end of the intervention.

    Time frame: Baseline and end of the 2-week intervention

  2. Change in Restless Legs Syndrome-Specific Quality of Life Assessed by the RLSQoL Questionnaire

    Restless legs syndrome-specific quality of life is assessed using the Restless Legs Syndrome Quality of Life Questionnaire (RLSQoL). Higher scores indicate better quality of life and a lower impact of restless legs syndrome. The outcome is the change in the RLSQoL score from baseline to the end of the intervention.

    Time frame: Baseline and end of the 2-week intervention

  3. Change in Health-Related Quality of Life Assessed by the EQ-5D

    Health-related quality of life is assessed using the EQ-5D questionnaire. The outcome is the change in EQ-5D score from baseline to the end of the intervention.

    Time frame: Baseline and end of the 2-week intervention

  4. Adherence to the Home-Based Exercise Program

    Adherence is assessed as the proportion of participants that completed the intervention period.

    Time frame: After the 2-week intervention

07

Study locations

1 site
  • Asociación Española de Piernas Inquietas (AESPI)
    Madrid, Spain
08

References and documents

Publications

  • Singh H, Baker FC, Ojile J, Adlou B, Kolotovska V, Rigot SK, Charlesworth JD. Efficacy and safety of TOMAC for treatment of medication-naive and medication-refractory restless legs syndrome: A randomized clinical trial and meta-analysis. Sleep Med. 2024 Oct;122:141-148. doi: 10.1016/j.sleep.2024.08.017. Epub 2024 Aug 18. PubMed 39173210 ↗
  • Thakur A, Sharma R, Sharma SK, Thakur K, Jelly P. Effect of buerger allen exercise on foot perfusion among patient with diabetes mellitus: A systematic review & meta-analysis. Diabetes Metab Syndr. 2022 Feb;16(2):102393. doi: 10.1016/j.dsx.2022.102393. Epub 2022 Jan 13. PubMed 35085917 ↗
  • Rodrigues E, Pontes AR, Brochado G, Bessa I, Carvalho P, Crasto C. Immediate effects of Global Active Stretching on strength and flexibility: Randomised Controlled Trial. S Afr J Sports Med. 2024 Aug 15;36(1):v36i1a16618. doi: 10.17159/2078-516X/2024/v36i1a16618. eCollection 2024. PubMed 39234297 ↗
  • Ratnani G, Harjpal P. Advancements in Restless Leg Syndrome Management: A Review of Physiotherapeutic Modalities and Their Efficacy. Cureus. 2023 Oct 10;15(10):e46779. doi: 10.7759/cureus.46779. eCollection 2023 Oct. PubMed 37954781 ↗
  • Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, Zucconi M, Ferri R, Trenkwalder C, Lee HB; International Restless Legs Syndrome Study Group. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med. 2014 Aug;15(8):860-73. doi: 10.1016/j.sleep.2014.03.025. Epub 2014 May 17. PubMed 25023924 ↗

Individual participant data

Plan to share: No — There is no plan to make individual participant data (IPD) available to external researchers. The study protocol and participant information and consent documents did not prospectively establish a mechanism for sharing participant-level data outside the study research team.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2026 to primary completion in Jul 2026, 4 months.

Of 46 non-industry interventional studies with no phase under Restless Legs Syndrome, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 42. This study's 4 months is below that.

Counting every sponsor, half of 53 studies reached it within 12 months; a quarter within 5 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2026
First posted
Sep 9, 2026
StartActual
Mar 3, 2026
Primary completionActual
Jul 22, 2026
CompletionActual
Jul 22, 2026
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07810127
Lead sponsor
Universidad Pontificia Comillas
Collaborators
Asociación Española de Síndrome de Piernas Inquietas (AESPI), Hospital Ruber Internacional
Responsible party
Sponsor
First posted
Sep 9, 2026
Start date
Mar 3, 2026
Primary completion
Jul 22, 2026
Completion
Jul 22, 2026
Last update
Sep 9, 2026

Study contacts

Laura Lillo Triguero, MD
principal investigator · Hospital Ruber Internacional

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion